132 related articles for article (PubMed ID: 35930599)
1. Estrogen receptor variant ER-α36 facilitates estrogen signaling via EGFR in glioblastoma.
Qu C; Wang C; Li H; Li Y; Han C; Tao X; Guan X; Zhang Y; Chen M; Liu J; Zou W
Cell Biol Int; 2022 Nov; 46(11):1759-1774. PubMed ID: 35930599
[TBL] [Abstract][Full Text] [Related]
2. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.
Zhang XT; Kang LG; Ding L; Vranic S; Gatalica Z; Wang ZY
Oncogene; 2011 Feb; 30(7):770-80. PubMed ID: 20935677
[TBL] [Abstract][Full Text] [Related]
3. The location of estrogen receptor variant ER-α36 is associated with the invasion of glioblastoma.
Li H; Ge N; Guan X; Han C; Li Y; Shen L; Chen M; Zhang B; Qu C; Zou W
Steroids; 2023 Jun; 194():109224. PubMed ID: 36924815
[TBL] [Abstract][Full Text] [Related]
4. Involvement of ER-α36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells.
Zhang XT; Ding L; Kang LG; Wang ZY
Oncol Rep; 2012 Jun; 27(6):2057-65. PubMed ID: 22426783
[TBL] [Abstract][Full Text] [Related]
5. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
Zhang X; Deng H; Wang ZY
J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
[TBL] [Abstract][Full Text] [Related]
6. The ER-α36/EGFR signaling loop promotes growth of hepatocellular carcinoma cells.
You H; Meng K; Wang ZY
Steroids; 2018 Jun; 134():78-87. PubMed ID: 29481815
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor variant ER-α36 promotes tamoxifen agonist activity in glioblastoma cells.
Qu C; Ma J; Zhang Y; Han C; Huang L; Shen L; Li H; Wang X; Liu J; Zou W
Cancer Sci; 2019 Jan; 110(1):221-234. PubMed ID: 30417588
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells.
Zhang X; Ding L; Kang L; Wang ZY
PLoS One; 2012; 7(1):e30174. PubMed ID: 22276155
[TBL] [Abstract][Full Text] [Related]
9. ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.
Zhu L; Zou J; Zhao Y; Jiang X; Wang Y; Wang X; Chen B
J Exp Clin Cancer Res; 2018 Jun; 37(1):123. PubMed ID: 29940998
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.
Wang ZY; Yin L
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453
[TBL] [Abstract][Full Text] [Related]
11. ER-α36 mediates estrogen-stimulated MAPK/ERK activation and regulates migration, invasion, proliferation in cervical cancer cells.
Sun Q; Liang Y; Zhang T; Wang K; Yang X
Biochem Biophys Res Commun; 2017 Jun; 487(3):625-632. PubMed ID: 28435071
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
[TBL] [Abstract][Full Text] [Related]
14. A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells.
Kang L; Guo Y; Zhang X; Meng J; Wang ZY
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):262-8. PubMed ID: 21907803
[TBL] [Abstract][Full Text] [Related]
15. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
[TBL] [Abstract][Full Text] [Related]
16. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.
Tong JS; Zhang QH; Wang ZB; Li S; Yang CR; Fu XQ; Hou Y; Wang ZY; Sheng J; Sun QY
PLoS One; 2010 Nov; 5(11):e15408. PubMed ID: 21079811
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors.
Gu Y; Chen T; López E; Wu W; Wang X; Cao J; Teng L
J Transl Med; 2014 Jan; 12():16. PubMed ID: 24447535
[TBL] [Abstract][Full Text] [Related]
18. Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.
Shi YE; Chen Y; Dackour R; Potters L; Wang S; Ding Q; Wang Z; Liu YE
Am J Pathol; 2010 Aug; 177(2):964-73. PubMed ID: 20595634
[TBL] [Abstract][Full Text] [Related]
19. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling.
Kang L; Zhang X; Xie Y; Tu Y; Wang D; Liu Z; Wang ZY
Mol Endocrinol; 2010 Apr; 24(4):709-21. PubMed ID: 20197310
[TBL] [Abstract][Full Text] [Related]
20. ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells.
Deng H; Zhang XT; Wang ML; Zheng HY; Liu LJ; Wang ZY
PLoS One; 2014; 9(2):e88034. PubMed ID: 24558373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
